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The minireview by Hemajarata et al. (1) is timely since the global incidence ofmelioidosis has probably been grossly underestimated (2). However, the review
reﬂects a very U.S. “select agent”-orientated perspective. In some parts of the world,
laboratories isolate Burkholderia pseudomallei on an almost daily basis; our own labo-
ratories diagnose more than 600 cases of culture-positive melioidosis each year, giving
us a different perspective.
The case described by Hemajarata et al. originated in the Philippines, but they do
not mention the fact that only exported cases have been reported in the literature
(3–10), implying underdiagnosis of indigenous melioidosis in the Philippines. Unfortu-
nately, even where laboratories exist in areas where melioidosis is endemic, they often
misidentify the organism or report it as Pseudomonas sp. (11, 12). We recommend that
any oxidase-positive, Gram-negative bacillus that is not obviously Pseudomonas aerugi-
nosa, isolated from any normally sterile clinical specimen, should be tested to exclude
B. pseudomallei. In resource-constrained settings, an oxidase-positive Gram-negative
rod from a clinical sample that is resistant to gentamicin and polymyxin/colistin but
susceptible to co-amoxiclav has a very high probability of being B. pseudomallei, with
the exception of isolates from Sarawak, 80% of which are susceptible to gentamicin (as
is B. mallei) (13).
In the case reported by Hemajarata et al., postexposure antimicrobial prophylaxis
(PEP) was given to nine employees, of whom two developed adverse reactions severe
enough to warrant a change of agent. Yet, as the authors note, there have only ever
been two well-described cases of laboratory-acquired melioidosis, both of which
followed major lapses in laboratory technique (14, 15). More cases of laboratory-
acquired glanders have been described (16, 17), implying that B. mallei may present a
greater risk to laboratory workers than B. pseudomallei, although many of these
occurred at a time when routine biosafety practice was likely to have been less
stringent than it is today. Furthermore, the efﬁcacy of PEP in protecting humans from
developing melioidosis remains unknown; in animal models, PEP frequently merely
delays the onset of disease, rather than preventing it (18). Diagnostic laboratories in
areas where melioidosis is endemic handle thousands of isolates of B. pseudomallei at
containment levels less stringent than U.S. biosafety level 3, and yet none of us has ever
been consulted about a case of conﬁrmed laboratory-acquired infection in over 70
Citation Dance DAB, Limmathurotsakul D,
Currie BJ. 2017. Burkholderia pseudomallei:
challenges for the clinical microbiology
laboratory—a response from the front line.
J Clin Microbiol 55:980–982. https://doi.org/
10.1128/JCM.02378-16.
Editor Alexander J. McAdam, Boston Children's
Hospital
Copyright © 2017 Dance et al. This is an open-
access article distributed under the terms of
the Creative Commons Attribution 4.0
International license.
Address correspondence to David A. B. Dance,
david.d@tropmedres.ac.
For the author reply, see https://doi.org/
10.1128/JCM.02438-16.
LETTER TO THE EDITOR
crossm
March 2017 Volume 55 Issue 3 jcm.asm.org 980Journal of Clinical Microbiology
years of combined experience, suggesting that the risk of laboratory-acquired infection
with B. pseudomallei is far lower than the risk of infection with some other hazard group
3 agents such as Brucella species or Francisella tularensis. This should be taken into
account when conducting risk assessments to inform the need for PEP, the hazards of
which are not themselves insigniﬁcant; co-trimoxazole, for example, is a well-
recognized cause of Stevens-Johnson syndrome (19). We very rarely end up recom-
mending PEP against melioidosis for laboratory workers and suspect that it is likely to
have been unnecessary in most, if not all, of the staff in this instance.
There is also confusion about when PEP should be used, which may partly reﬂect
differences between the consensus guidelines of Peacock et al. (20) cited in the review
and the earlier Morbidity and Mortality Weekly Report guidance that they superseded
(21). Hemajarata et al. incorrectly state that PEP is recommended for all low-risk
exposures, whereas it is only advised for those who have underlying risk factors that
predispose them to melioidosis (20). We believe that a more rational approach to PEP
will be achieved if B. pseudomallei is regarded as a naturally occurring, geographically
restricted, opportunistic pathogen instead of solely being demonized as a “select
agent” (22). Death from melioidosis is very uncommon in healthy people if timely
diagnosis, institution of appropriate antibiotics, and state-of-the-art intensive care
management are available (23). Nevertheless, there remains a danger that the anxiety
generated in this era of “the war on terror”; for example, the “STOP” algorithm for
laboratories included in the review by Hemarajata et al. may adversely affect patient
diagnosis, management, and outcomes.
We agree that urine and throat swabs should always be cultured for patients with
suspected melioidosis. However, nearly one-third of cases will have B. pseudomallei
counts of103 CFU/ml in urine, and it is therefore important to culture the centrifuged
deposit, ideally on a selective medium such as Ashdown’s agar (not MacConkey agar),
for optimal sensitivity (24). Throat swabs also need to be cultured on selective agar such
as Ashdown’s agar and ideally also pre-enriched in selective broth media (25).
If the results of recent modeling studies are correct, melioidosis is a far bigger killer
of humans than diseases that are much better known, such as leptospirosis and dengue
(2). As the prevalence of diabetes mellitus increases in areas where melioidosis is
endemic and as climate change results in more severe weather events, it is likely to
become even more common. Clinical laboratories thus need to be ready to identify B.
pseudomallei and think of it as a not uncommon cause of naturally occurring infection
in much of the world. We hope that these observations from the “front line” will
encourage this.
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